Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

249 Press Releases
DateTitleCompany
26 Jul 17 Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students Shire plc,
Published by
GlobeNewswire
18 Jul 17 Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire plc,
Published by
GlobeNewswire
18 Jul 17 Shire plc : Notice of Results Shire plc,
Published by
GlobeNewswire
06 Jul 17 Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A Shire plc,
Published by
GlobeNewswire
06 Jul 17 Shire plc : Additional Listing Shire plc,
Published by
GlobeNewswire
03 Jul 17 Shire plc : Total voting rights Shire plc,
Published by
GlobeNewswire
26 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire ,
Published by
PharmiWeb.com
26 Jun 17 Shire to present new data at ISTH 2017 to advance the standard of care in Hemophilia Shire,
Published by
PharmiWeb.com
26 Jun 17 Shire announces EMA validation of VEYVONDI™ [von Willebrand factor (Recombinant)] Marketing Authorization Application for treatment of von Willebrand disease Shire,
Published by
PharmiWeb.com
26 Jun 17 Director Declaration Shire,
Published by
PharmiWeb.com
23 Jun 17 SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA Shire Pharmaceuticals Group,
Published by
GlobeNewswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
26 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire ,
Published by
PharmiWeb.com
25 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire plc,
Published by
PR Newswire
22 May 17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis Shire ,
Published by
PharmiWeb.com
16 May 17 Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association Shire plc,
Published by
PR Newswire
18 May 17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis Shire plc,
Published by
PR Newswire
19 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire plc,
Published by
PR Newswire
21 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire ,
Published by
PharmiWeb.com
01 May 17 Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
04 May 17 Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications Shire ,
Published by
PharmiWeb.com
18 May 17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire plc,
Published by
PR Newswire
22 May 17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire,
Published by
PharmiWeb.com
18 May 17 Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.